2024
Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucel
2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
Bar N, Costa F, Das R, Duffy A, Samur M, McCachren S, Gettinger S, Neparidze N, Parker TL, Bailur JK, Pendleton K, Bajpai R, Zhang L, Xu ML, Anderson T, Giuliani N, Nooka A, Cho HJ, Raval A, Shanmugam M, Dhodapkar KM, Dhodapkar M. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer. JCI Insight 2020, 5 PMID: 32427579, PMCID: PMC7406262, DOI: 10.1172/jci.insight.129353.Peer-Reviewed Original ResearchConceptsPD-L1 blockadePD-1 blockadeAsymptomatic multiple myelomaMonocyte-derived DCsPD-L1Immunologic effectsT cellsMyeloid cellsAntigen-specific T cell expansionAnti-PD-1 therapyMyeloid antigen-presenting cellsDistinct inflammatory signatureSystemic immunologic effectsLung cancer patientsT cell expansionAntigen-presenting cellsMyeloid activationMyeloid inflammationInflammatory signatureNIH/NCICheckpoint blockadeDC maturationL1 therapyCombination therapyInflammatory phenotype
2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy
Bailur JK, McCachren SS, Doxie DB, Shrestha M, Pendleton K, Nooka AK, Neparidze N, Parker TL, Bar N, Kaufman JL, Hofmeister CC, Boise LH, Lonial S, Kemp ML, Dhodapkar KM, Dhodapkar MV. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight 2019, 5 PMID: 31013254, PMCID: PMC6629164, DOI: 10.1172/jci.insight.127807.Peer-Reviewed Original ResearchMeSH KeywordsBone MarrowCell Transformation, NeoplasticFemaleGene Expression Regulation, NeoplasticHepatocyte Nuclear Factor 1-alphaHumansImmunity, InnateImmunologic MemoryImmunologic SurveillanceIntercellular Signaling Peptides and ProteinsMaleMiddle AgedMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaMyeloid CellsPrecancerous ConditionsRNA-SeqSingle-Cell AnalysisStem CellsT-LymphocytesTumor MicroenvironmentConceptsMemory T cellsSingle-cell transcriptome analysisT cellsMyeloid cellsMyeloma patientsTerminal effector differentiationImmune cellsHealthy donorsProlonged dormancyTranscriptome analysisBone marrowBone marrow immune cellsStem-like cellsStem-like T cellsAge-matched healthy donorsDistinct genomic profilesResident T cellsSingle immune cellsT cell compartmentBone marrow plasmaCell compartmentGenomic profilesCancer cellsPreneoplastic gammopathyImmune microenvironment
2011
Understanding the Role of Natural Killer T Cells in Hematologic Malignancies: Progress and Challenges
Neparidze N, Dhodapkar M. Understanding the Role of Natural Killer T Cells in Hematologic Malignancies: Progress and Challenges. Cancer Drug Discovery And Development 2011, 153-167. DOI: 10.1007/978-1-4614-0613-6_9.Peer-Reviewed Original ResearchNatural killer T cellsKiller T cellsNKT cellsHematologic malignanciesT cellsImportant effector cellsPreliminary clinical studyAnti-tumor effectsNKT functionDendritic cellsTumor immunityEffector cellsHematologic tumorsClinical studiesMalignancyQualitative defectsPatientsCD1dType IAttractive targetCellsVivoClinicNKTTumors
2009
Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans
Neparidze N, Dhodapkar MV. Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans. Annals Of The New York Academy Of Sciences 2009, 1174: 61-67. PMID: 19769737, PMCID: PMC2782771, DOI: 10.1111/j.1749-6632.2009.04931.x.Peer-Reviewed Original ResearchConceptsNKT cellsT cellsAntitumor immunityType I NKT cellsType II NKT cellsNatural killer T cellsPresence of CD1dI NKT cellsKiller T cellsAdvanced myelomaNKT activationDendritic cellsImmune therapyAlpha-GalactosylceramideCancer patientsCD1d moleculesLipid antigensPreclinical studiesThalidomide analoguesCD1dDistinct subsetsAgonist ligandsPatientsCancerType I